Antibiotic resistance in nosocomial respiratory infections

Clinics in Laboratory Medicine

Volumn 34, Issue 2, 2014, Pages 257-270

  Denys, Gerald A ^a   Relich, Ryan F ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Health care associated infections; Hospital acquired pneumonia; Multidrug resistant pathogens; Nosocomial; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; BIOSENSOR; DIAGNOSTIC KIT; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; MASS SPECTROMETER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROARRAY KIT; MORAXELLA CATARRHALIS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PATHOGENESIS; PATIENT CARE; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIUM; CROSS INFECTION; DRUG EFFECTS; HUMAN; MICROBIOLOGY; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

ANTI-BACTERIAL AGENTS; BACTERIA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84901282961     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2014.02.004     Document Type: Review

References (50)

1. Spellberg B., Blaser M., Guidos R.J., et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011, 52(Suppl 5):S397-S428.
2. Sievert D.M., Ricks P., Edwards J.R., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013, 34(1):1-14.
3. National Nosocomial Infections Surveillance (NNIS) System National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32:470-485.
4. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care cost. Clin Infect Dis 2006, 42(Suppl 2):S82-S89.
5. Holmberg S.D., Solomon S.L., Blake P.A. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987, 9:1065-1078.
6. Niederman M.S., Craven D.E., Bonten M.J. American Thoracic Society and Infectious Disease Society of America (ATS/IDSA): guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
7. Barbier F., Andremont A., Wolff M., et al. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013, 19(3):216-228.
8. Vincent J.L., Rello J., Marshall J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
9. Rosenthal V.D., Bijie H., Maki D.G., et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012, 40:396-407.
10. Sydnor E.R., Perl T.M. Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev 2011, 24:141-173.
11. Jones R.N. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010, 51(Suppl 1):S81-S87.
12. Papazian L, Donati SY. Hospital-acquired pneumonia. In: Cohen J, Powderly WG, Opel SM, editors. van der Meer JWM, Didier, Sobel JD, section editors. Cohen, Powderly and Opal's infectious diseases. 3rd edition. Philadelphia: Mosby Elsevier; 2010. p. 294-9.
13. Safder N., Crnich C.J., Maki D.G. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir Care 2005, 50:725-739.
14. Ferrer M., Liapikou A., Valencia M., et al. Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. Clin Infect Dis 2010, 50:945-952.
15. Popovich K.J., Weinstein R.A., Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?. Clin Infect Dis 2008, 46:787-794.
16. De Lassence A., Hidri N., Timsit J.F., et al. Control and outcome of a large outbreak of colonization and infection with glycopeptides-intermediate Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2006, 42:170-178.
17. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007, 44:1543-1548.
18. Morales G., Picazo J.J., Baos E., et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010, 50:821-825.
19. Sánchez Garcia M., De la Torre M.A., Morales G., et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303:2260-2264.
20. Nordmann P., Naas T., Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 17:1791-1798.
21. Centers for Disease Control and Prevention (CDC) Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013, 62:165-170.
22. Tzouvelekis L.S., Markogiannakis A., Psichogiou M., et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25(4):682-707.
23. Roy-Burman A., Savel R.H., Racine S., et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. JInfect Dis 2001, 183:1767-1774.
24. Chung D.R., Song J.H., Kim S.H., et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011, 184:1409-1417.
25. Livermore D.M. Has the era of untreatable infections arrived?. JAntimicrob Chemother 2009, 64(Suppl 1):i29-i36.
26. Antoniadou A., Kontopidou F., Poulakou G., et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. JAntimicrob Chemother 2007, 59:786-790.
27. Bogdanovich T., Adams-Haduch J.M., Tian G.B., et al. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis 2011, 53:373-376.
28. Pucci M.J., Bush K. Investigational antimicrobial agents of 2013. Clin Microbiol Rev 2013, 26(4):792-821.
29. Kieninger A.N., Lipsett P.A. Hospital-acquired pneumonia: pathophysiology, diagnosis, and treatment. Surg Clin North Am 2009, 89:439-461.
30. Craven D.E., Chroneou A. Chapter 303, nosocomial pneumonia. Mandell, Douglas, and Bennett's principles and practices of infectious diseases 2010, 3717-3724. Churchill Livingstone Elsevier, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
31. Jean S.S., Hsueh P.R. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin Pharmacother 2011, 12(14):2145-2148.
32. Joseph N.M., Sistla S., Dutta T.K., et al. Role of intensive care unit environment and health-care workers in transmission of ventilator-associated pneumonia. JInfect Dev Ctries 2010, 4(5):282-291.
33. Rotstein C., Evans G., Born A., et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol 2008, 19(1):19-53.
34. 2007 update: clinical microbiology procedures handbook 2007, ASM Press, Washington, DC. 2nd edition. L.S. Garcia (Ed.).
35. Gilbert D.N., Spellberg B., Bartlett G. An unmet medical need: rapid molecular diagnostic tests for respiratory tract infections. Clin Infect Dis 2011, 52(Suppl 4):S386-S395.
36. Lung M., Codina G. Molecular diagnosis in HAP/VAP. Curr Opin Crit Care 2012, 18(5):487-494.
37. Tenover F.C. Developing molecular amplification methods for rapid diagnosis of respiratory tract infections caused by bacterial pathogens. Clin Infect Dis 2011, 52(Suppl 4):S338-S345.
38. Endimiani A., Hujer K.M., Hujer A.M., et al. Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?. Clin Infect Dis 2011, 52(Suppl 4):S373-S383.
39. Endimiani A., Hujer A.M., Hujer K.M., et al. Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in Gram-negative isolates. JClin Microbiol 2010, 48:2618-2622.
40. Card R., Zhang J., Das P., et al. Evaluation of an expanded microarray for detecting antibiotic resistance genes in a broad range of gram-negative bacterial pathogens. Antimicrob Agents Chemother 2013, 57:458-465.
41. Cercenado E., Marin M., Burillo A., et al. Rapid detection of Staphylococcus aureus in lower respiratory tract secretions from patients with suspected ventilator-associated pneumonia: evaluation of the Cepheid Xpert MRSA/SA SSTI assay. JClin Microbiol 2012, 50:4095-4097.
42. Fagon J.Y. Biological markers and diagnosis of ventilator-associated pneumonia. Crit Care 2011, 15:130.
43. Luyt C.E., Combes A., Reynaud C., et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008, 34:1434-1440.
44. Linssen C.F., Bekers O., Drent M., et al. C-reactive protein and procalcitonin concentrations in bronchoalveolar lavage fluid as a predictor of ventilator-associated pneumonia. Ann Clin Biochem 2008, 45:293-298.
45. Gibot S., Kolopp-Sarda M.N., Béné M.C., et al. Plasma level of a triggering expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004, 141(1):9-15.
46. Anand N.J., Zuick S., Klesney-Tait J., et al. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary patients in the ICU. Chest 2009, 135:641-647.
47. Iregui M., Ward S., Sherman G., et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122:262-268.
48. Petrosillo N., Giannella M., Russel L., et al. Treatment of carbapenem-resistant Klebsiella pneumoniae. Expert Rev Anti Infect Ther 2013, 11(2):159-177.
49. Tablan O.C., Anderson L.J., Besser R., et al. Guidelines for preventing health-care associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004, 53:1-36.
50. Koenig S.M., Jonathon D.T. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev 2006, 19(4):637-657.